Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus
Copyright © 2020. Published by Elsevier Ltd..
Recent advances in virus-like nanoparticles against Middle East respiratory syndrome-related coronavirus (MERS-CoV) can initiate vaccine production faster for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), while ensuring the safety, easy administration, and long-term effects. Patients with this viral pathogen suffer from excess mortality. MERS-CoV can spread through bioaerosol transmission from animal or human sources. The appearance of an outbreak in South Korea sparked off a strong urge to design strategies for developing an effective vaccine since the emergence of MERS-CoV in 2012. Well unfortunately, this is an important fact in virus risk management. The studies showed that virus-like nanoparticles (VLPs) could be effective in its goal of stopping the symptoms of MERS-CoV infection. Besides, due to the genetic similarities in the DNA sequencing of SARS-CoV-2 with MERS-CoV and the first identified severe acute respiratory syndrome (SARS-CoV) in China since 2002/2003, strategic approaches could be used to manage SARS-CoV 2. Gathering the vital piece of information obtained so far could lead to a breakthrough in the development of an effective vaccine against SARS-CoV-2, which is prioritized and focussed by the World Health Organization (WHO). This review focuses on the virus-like nanoparticle that got successful results in animal models of MERS-CoV.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
Vaccine - 38(2020), 36 vom: 10. Aug., Seite 5742-5746 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hashemzadeh, Alireza [VerfasserIn] |
---|
Links: |
---|
Themen: |
Coronavirus |
---|
Anmerkungen: |
Date Completed 11.08.2020 Date Revised 02.03.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.vaccine.2020.07.003 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312608098 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312608098 | ||
003 | DE-627 | ||
005 | 20231225144757.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2020.07.003 |2 doi | |
028 | 5 | 2 | |a pubmed24n1041.xml |
035 | |a (DE-627)NLM312608098 | ||
035 | |a (NLM)32684497 | ||
035 | |a (PII)S0264-410X(20)30903-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hashemzadeh, Alireza |e verfasserin |4 aut | |
245 | 1 | 0 | |a Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.08.2020 | ||
500 | |a Date Revised 02.03.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
520 | |a Recent advances in virus-like nanoparticles against Middle East respiratory syndrome-related coronavirus (MERS-CoV) can initiate vaccine production faster for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), while ensuring the safety, easy administration, and long-term effects. Patients with this viral pathogen suffer from excess mortality. MERS-CoV can spread through bioaerosol transmission from animal or human sources. The appearance of an outbreak in South Korea sparked off a strong urge to design strategies for developing an effective vaccine since the emergence of MERS-CoV in 2012. Well unfortunately, this is an important fact in virus risk management. The studies showed that virus-like nanoparticles (VLPs) could be effective in its goal of stopping the symptoms of MERS-CoV infection. Besides, due to the genetic similarities in the DNA sequencing of SARS-CoV-2 with MERS-CoV and the first identified severe acute respiratory syndrome (SARS-CoV) in China since 2002/2003, strategic approaches could be used to manage SARS-CoV 2. Gathering the vital piece of information obtained so far could lead to a breakthrough in the development of an effective vaccine against SARS-CoV-2, which is prioritized and focussed by the World Health Organization (WHO). This review focuses on the virus-like nanoparticle that got successful results in animal models of MERS-CoV | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a MERS-CoV | |
650 | 4 | |a Nanoparticles | |
650 | 4 | |a Vaccine | |
650 | 4 | |a Virus-like particles | |
650 | 7 | |a Vaccines, Virus-Like Particle |2 NLM | |
700 | 1 | |a Avan, Amir |e verfasserin |4 aut | |
700 | 1 | |a Ferns, Gordon A |e verfasserin |4 aut | |
700 | 1 | |a Khazaei, Majid |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 38(2020), 36 vom: 10. Aug., Seite 5742-5746 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2020 |g number:36 |g day:10 |g month:08 |g pages:5742-5746 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2020.07.003 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 38 |j 2020 |e 36 |b 10 |c 08 |h 5742-5746 |